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ABSTRACT. A large series of structurally related diethylenetriaminepentaacetic acid amide derivatives with
different structures and lipophilic properties were synthesized and radiolabeled with 111In31. Two of the
more hydrophobic compounds studied ([111In]L9 and [111In]L10) showed high affinity for human serum
albumin (HSA). The biodistribution and clearance properties shown by all complexes upon injection in
Wistar rats were followed by gamma imaging. The blood retention time of the chelates correlates better with
their binding to HSA than with their hydrophilic/lipophilic ratio. Hydrophilic and negatively charged
complexes undergo renal retention, while the majority of the lipophilic complexes are retained in the blood
for a longer period of time and are cleared through the liver. NUCL MED BIOL 27;6:605–610, 2000. © 2000
Elsevier Science Inc. All rights reserved.
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INTRODUCTION
Among the chelating agents that have found applications in
medicine, DTPAH5 (diethylenetriaminepentaacetic acid) remains
one of the most commonly used (14) because it forms stable
complexes with many cations (12) and allows the preparation of
bifunctional chelating derivatives, which can easily be linked to
high molecular weight compounds. [[111In](DTPA)]22 has been
described as an ideal agent for scintigraphic studies of the cerebro-
spinal fluid pathway (10, 14). DTPAH5 is also the ligand of choice
in one of the widely used magnetic resonance imaging (MRI)
contrast agents [Gd(III)(DTPA)]22 (Magnevist: Berlex; Wayne,
NJ, USA) (31). One of the important characteristics of this ligand
is that it allows functionalization via the carboxylic functional
groups simply by using the DTPA-bisanhydride as a precursor (15,
23). The DTPA amide derivatives (either bisamides or monoamide)
possess the same number of donor atoms (three nitrogens and five
oxygens) as DTPAH5, with a reduction of ionizable groups. These
acyclic ligands have some advantages relative to macrocyclic
analogues in biomedical applications because of their much higher
complexation rates and their higher flexibility in coordinating
cations compared to the macrocyclic compounds, although their
generally faster dissociation kinetics and lower thermodynamic
stability can constitute serious disadvantages (27).
DTPAH5 is an octadentate ligand that can bind to a metal ion
through five deprotonated carboxylate groups and the three tertiary
amino groups (21). In the past, we had prepared a series of new
DTPA mono and bis-amides (Fig. 1) by derivatizing one or two of
the DTPAH5 carboxylate groups to amide functionalities with a
variety of substituents (2, 8). For some of them, the solution
structure and dynamics of their In31 complexes and their thermo-
dynamic stability constants were obtained, with a small decrease in
the thermodynamic stability of those chelates relative to
[In31DTPA]22 (8).
In this work we report some in vitro and in vivo properties of this
series of 111In31 complexes, comparing them with the known
behavior of [[111In](DTPA)]22 (10, 11), relevant for the assessment
of the potential applications of the DTPA amide chelates in nuclear
medicine. The ligands (L1 to L13) form a series of neutral or
negatively charged complexes with In31 with varying molecular
properties, in particular, with a different lipophilic/hydrophilic
character. An increased hydrophobicity may lead to stronger
interactions of these chelates, for example, with proteins such as
human serum albumin (HSA) or lipophilic entities, potentially
altering their biodistribution. The factors determining biliary versus
urinary excretion are chiefly influenced by three main chelate
properties: polarity, molecular size and weight, and structure (4, 5,
18, 19). Here we also assess the correlation of the observed in vitro
and in vivo behavior of these 111In31 complexes with those
molecular properties, contributing to the design of new and more
specific radiopharmaceuticals.
MATERIALS AND METHODS
Reagents and Apparatus
[111In]Cl3 was obtained from CIS-Biointernational (Sarclay,
France); instant thin layer chromatography-silica gel (ITLC-SG)
was from Gelman Sciences, Inc. (Ann Arbor, MI, USA); HSA
(crystallized and lyophilized) was from Sigma (Madrid, Spain). All
the ligands used in this work were synthesized and characterized as
described elsewhere (1, 2, 8, 9, 16). Other reagents and solvents
were obtained from either Aldrich or Sigma and were used as
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received. All reagents for in vivo use were prepared sterile and
pyrogen-free. A gamma camera-computer system (GE 400
GenieAcq, General Electric, Milwaukee, WI, USA) was used for
acquisition and preprocessing. Data processing and display were
performed on a personal computer using homemade software devel-
oped for the IDL 5.2 computer tool. A g well-counter (DPC-
Gamma C12) with a Compaq DeskPro compatible computer was
used for activity counting in the biodistribution studies.
Determination of 1-Octanol/Saline Partition Coefficients
111In31 complexes were prepared in distilled water by mixing the
ligand with [111In]Cl3 (in a 10:1 ratio) and adjusting the pH to
approximately 7 with 0.1 M NaOH. The partition coefficients were
determined by addition of 25 mL of 111In31-chelate solution in a
test tube containing 1 mL of saline solution and 1 mL of 1-octanol.
The tubes were vortexed and centrifuged for 3 min at 3,000 rpm.
Then, aliquots of 100 mL of each phase were taken for radioactivity
counting. The partition coefficients were calculated by dividing the
net radioactivity counting of the organic phase by that of the
aqueous phase. The results presented are the means of five deter-
minations (with an SD of ,0.01).
Calculation of 1-Octanol/Water Partition Coefficients
The 1-octanol/water partition coefficients for the free ligands (L1 to
L10) were calculated using the log KOW program from SRC
(Syracuse Research Corporation, New York, NY, USA) using a
SMILE (Simplified Molecular Input Line Entry System) notation to
represent each molecule. The calculations were based upon the
additive-constitutive character of the partition coefficient (P) and
the use of a substituent constant px, which is defined as Eq. (1)
(7, 20):
px 5 log Px 2 log PH (1)
where Px is the partition coefficient of the derivative of a parent
molecule with a partition coefficient PH.
Interaction of Human Serum Albumin with 111In31
Chelates
Albumin solutions were freshly prepared by dissolving HSA in
HEPES 0.1 M buffer to obtain 0.6 mM concentration (assuming
69 KDa as the HSA molecular weight). 0.2-mM L9 and L10 water
solutions were labeled with a small amount of [111In]Cl3 (in 0.1 N
HCl), and afterwards InCl3 (nonradioactive indium chloride) was
added to obtain a 1:1 complex. These solutions were mixed with
2 mL of the HSA solution and were continuously stirred for 6 h and
then left overnight at room temperature. A 1 mL sample was then
dialyzed for 24 h, through membranes retaining molecules above
12 KDa at 281 K (30). Aliquots were collected inside and outside
the membrane and counted in a g well-counter. Total protein
binding of InL chelates was calculated as percent of the applied InL
solution that was retained inside the membrane (30).
Gamma Imaging
Stock solutions of the ligands were prepared in isotonic HEPES
0.1 M buffer and mixed with [111In]Cl3 (0.1 N HCl) to obtain 1:1
111In31 complexes (with 10% ligand excess). The efficiency of
labeling of the ligands with 111In31 was checked by chromatogra-
phy (an ITLC-SG/butanone system), indicating that an approxi-
mately 100% radiochemically pure preparation of the complex was
achieved. Gamma images and biological distributions for the
111In31 complexes were determined using 300 g Wistar rats. All
animal studies were carried out in compliance with procedures
approved by the appropriate institutional review committees. Con-
scious rats were allowed free access of food and water ad libitum.
Groups of four animals (one group for each complex) were anaes-
thetized with Ketamine (50 mg/mL)/chloropromazine (2.5%)
(10:3) and injected in the tail vein with approximately 150 mCi of
the respective 111In31 chelate. The animals were then positioned in
dorsal decubitus over the detector. Image acquisition was initiated
immediately before radiotracer injection. Sequences of 180 images
(of 10 s each), were acquired to 64 3 64 matrices. Blood samples
were taken during the dynamic acquisition (at 5, 15, and 30 min)
and subsequently counted in a g well-counter. The clearance of
radiotracer over time was followed by time-activity curves on
images obtained from three regions of interest, thorax, liver, and left
kidney. In addition, static data were acquired at 24, 48, and 72 h
after the radiotracer injection.
Biodistribution Studies
Groups of four animals were injected with approximately 100 mCi
of the complexes and sacrificed 2 h later. The major organs (liver,
spleen, left kidney, heart, lung, intestines, brain) were removed,
weighed, and counted in a g well-counter.
RESULTS AND DISCUSSION
Partition Coefficients
The binding of a wide variety of nonionic organic compounds of
miscellaneous structures to both bovine serum albumin (BSA) and
bovine hemoglobin appears to depend almost exclusively on hydro-
phobic interactions and is linearly related to their octanol-water
partition coefficient (13). The partitioning between octanol and
water has been used to predict the ability of a compound to be
absorbed and to distribute out of the vascular compartment into
FIG. 1. Chemical structures of the
DTPA amide derivatives. Bis-
amides, L1 to L12, R1 5 R2 5 meth-
ylenephenyl (L1); ethylenephenyl
(L2); n-propyl (L3); n-butyl (L4);
cyclohexyl (L5); methylenecyclo-
hexyl (L6); 2-norbornyl (L7); me-
thinediphenyl (L8); 2-ethylhexyl
(L9); n-heptyl (L10); glucosyl (L11);
methoxyethyl (L12); monoamide,
R2 5 OH and R1 5 n-propyl (L
13).
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intracellular sites (17). In fact, this partition should model the lipid
solubility of metal complexes, allowing them to remain within
hepatocytes.
The octanol-saline partition coefficients determined for the
111In31 complexes of L2 and L5 to L10 are summarized in Table 1,
together with the computed values for the free ligands. Values were
compared with log P for [111InDTPA] taken from literature (24).
The log KOW program only allows calculations for covalent
molecules, which is not, obviously, the case of the 111In31 chelates.
Due to a poor extraction of the more hydrophilic 111In31 complexes
by 1-octanol, this type of determination only gave accurate results
for the less hydrophilic chelates. A good correlation between the
calculated log P values for the ligands and the experimental data for
the corresponding complexes was obtained. The only exception was
[111In]L7, possibly due to steric hindrance resulting from the
presence of the bulky norbornyl substituents, making this chelate
not isostructural with the others.
In Vitro Studies
The present HSA binding study was carried out only for some of the
more lipophilic In31 chelates that gave quite efficient binding: 80%
for [111In]L9 and 72% for [111In]L10. Some HSA binding studies of
Gd31-DTPA-bisamides have been published previously using water
proton relaxivity measurements, namely of GdL4 and GdL10,
qualitatively demonstrating some degree of HSA interaction for
GdL10 (9). A more recent relaxivity study with the Gd31 com-
plexes of some of the presently studied ligands, GdLi (i 5 1, 2, 5, 7,
9) (2), has suggested that the bisamide derivatives with greater
hydrophobic character may originate stronger interactions with
HSA, but the protein binding sites did not recognize aryl or
norbonyl side chains, as well as short substituent groups. The only
quantitative binding study for this series was for GdL9, with an
association constant KA 5 (5.7 6 1.3) 3 10
3 M21, giving a value
of 72% for the bound fraction of GdL9 (0.1 mM) in the presence of
0.6 mM HSA. Thus, the 80% HSA-bound fraction for InL9
measured in the same conditions in the present study is comparable
to that of GdL9.
In Vivo Studies
Figure 2 summarizes the percentage of injected dose/g of tissue
obtained from blood samples collected at 30 min after injection of
some of the most representative 111In31 complexes. While the
hydrophilic chelates are rapidly cleared, long retention times are
observed for the more hydrophobic chelates, [111In]L10 . [111In]L9.
[111In]L9 has a strong interaction with HSA, stronger than that of
[111In]L10, as evaluated from our studies, which agrees with quali-
tative binding studies with GdL10 (9), and its hydrophobicity as
measured by the log P values (Table 1) is higher than that of
111InL10. Its shorter retention in blood compared to [111In]L10
indicates that this parameter may not be exclusively related with
HSA binding.
Gamma Imaging
Figure 3 shows the averaged time-activity curves obtained from
dynamic acquisitions up to 30 min for two regions of interest (left
kidney and liver) using some representative complexes. The mean
thorax activity/pixel was considered as the background activity. The
values of mean activity/pixel for each region of interest (RI), after
background deduction, were used to obtain regional time/activity
curves. The curves were normalized relative to the maximum
activity obtained for each complex.
We can clearly divide the chelates studied into two main groups
according to their clearance pathway. For the more hydrophilic
111In31 chelates (with the ligands, L3, L4, and L11-L13), the kidney
activity/time curves, obtained from the dynamic acquisitions, gen-
erally show two different portions: an initial sharper one corre-
sponding to uptake and a slower second one corresponding to slower
clearance. This type of profile, exemplified in Figure 3 for [111In]L12
and [111In]L13, indicates that those complexes undergo some renal
retention. We would expect a more pronounced retention of
[111In]L13 (Fig. 3) when compared with the neutral hydrophilic
complexes due to its negative charge. Instead, we can notice from
Fig. 3 that these chelates have a very similar renal behavior. Some
of these hydrophilic complexes show a small amount of activity at
the liver-spleen region, which can be related with colloidal particles
of indium hydroxide trapped by the reticuloendothelial system.
However, the high thermodynamic stability of this type of com-
plexes [e.g., log K (InL4) 5 20.4] (8) seems to discard the
hypothesis of premature dissociation of these 111In31 chelates. In a
previous study (25), we reported the in vitro stability of 111In31
complexes of L4 in blood serum and concluded that it has low
dissociation (0.30% after 24 h), comparable to [[111In]DTPA]22
(1.5% after 24 h) (26), indicating that conditional stability (defined
as stability of the chelates at physiological conditions) is more
important than thermodynamic stability to rationalize in vivo
TABLE 1. Measured 1-Octanol/Saline Partition Coefficients
for 111In31 Complexes and Calculated Values for the Free
Ligands
Ligand Log Pa [111In]L Log Pb
L1 24.26 [111In]L1 –
L2 23.27 [111In]L2 21.23
L3 25.71 [111In]L3 –
L4 24.73 [111In]L4 –
L5 23.13 [111In]L5 20.4
L6 22.15 [111In]L6 0.07
L7 21.27 [111In]L7 21.28
L8 20.99 [111In]L8 0.31
L9 20.94 [111In]L9 1.08
L10 21.78 [111In]L10 20.33
DTPA – [111In]DTPA 22.86c
a Calculated.
b Experimental.
c (24).
FIG. 2. Mean total %ID/g blood at 30 min after IV adminis-
tration of some of the [111In] chelates studied.
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stability in blood serum. The thorax curve corresponds, in all the
cases, only to blood activity.
The 111In31 complexes obtained with the ligands L1, L2, L6, L9,
and L10 show a very different clearance pathway, which may be
related to their increased lipophilicity. For the 111In31 complexes of
L1, L2, L6 (Fig. 3), L9 (Fig. 3), and L10, a pronounced uptake in the
first few seconds was followed by a period of slow elimination of the
radiotracer. This behavior suggests the implication of the liver in
the metabolism of these complexes. Figure 4 shows the scintigraphic
images of rats at 30 min after the injection of [111In]L6 and
[111In]L12. For the more lipophilic complexes, almost all the
radioactivity was at the intestines, corresponding to the excretory
phase of the chelates. However, a small activity in the bladder is
also observed for most of these chelates, indicating that renal
clearance is also present.
In the images obtained at 24 and 48 h after injection of all the
111In31 complexes (data not shown), a residual activity in the
liver-spleen region was observed, possibly due to decomplexation
and precipitation of indium hydroxides. As the complexes are
thermodynamically quite stable (8), this fact should be related to
FIG. 3. Time-activity curves at the various regions of interest for (from left to right and top to bottom) [111In]L6, [111In]L9,
[111In]L12, [111In]L13. Grey line: activity/time curve for liver; black line: activity/time curve for left kidney.
FIG. 4. Scintigraphic images at 30 min after injection with (a) [111In]L6 and (b) [ 111]InL12.
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kinetic instability, which should influence their in vivo behavior
(27).
Biodistribution Studies
The results of animal biodistribution studies at 2 h (in percent of
injected dose per gram of organ or tissue) for the chelates studied are
summarized in Table 2, along with data for [[111In]DTPA]22,
obtained in our laboratory, for comparative purposes. [[111In]
DTPA]22 is an extracellular complex and is known to be eliminated
by glomerular filtration (10). Comparison of the images obtained at
30 min with the biodistribution data at 2 h shows that the
unexpected low activity values for liver and gastrointestinal tract for
L1, L2, L6, L9, and L10 were due to the rapid clearance of these
chelates. Particularly noticeable from Table 2 are the low values of
kidney activity for the latter chelates when compared with the
hydrophilic ones. Based on the values obtained for the partition
coefficients between octanol and water, we would not expect such
a pronounced liver uptake for [111In]L2, [111In]L6, [111In]L9, or
111[In]L10. This fact indicates that liver uptake is not only a
function of lipophilicity. Conversely, other less obvious parameters
govern the amount of radioactivity clearing through the liver as it
has been pointed out by other previous studies with 67Ga31 and
111In31 chelates (3, 22, 23, 24).
We found no evidence of bone uptake, which would reflect
uptake in the bone marrow that is seen when the In31-transferrin
complex is formed (28, 29). Thus, this is evidence that the chelates
remained intact for the time they stayed in blood. This agrees with
thermodynamic stability constants and pM values reported else-
where for some of these bis-amides chelates, which were found to be
higher than that determined for the In31-transferrin complex (8),
the main competitor for In31 and Ga31 in blood (28, 29).
None of the complexes passed through the blood-brain barrier, as
expected for high molecular weight and/or low lipophilic com-
plexes. In fact, several authors have estimated the molecular weight
cut-off for brain extraction to be between 400 and 600 for
substances with log P . 2 (6, 18).
CONCLUSION
In this work, we have used a large series of bisamide ligands (and
one monoamide), previously synthesized, based on the structure of
DTPAH5, and have shown that simple substitutions in this ligand
can cause major alterations in the biodistribution and clearance of
their 111In31 chelates. While the more hydrophilic complexes clear
by the kidneys, the more lipophilic chelates clear by the liver and
gastrointestinal tract, thus demonstrating the influence of lipophi-
licity in the clearance of these 111In31 chelates. However, within
this later group, the observed liver uptake is much more pronounced
than what would be expected based on their experimental log P
values. This clearly illustrates that liver uptake is not just a simple
function of lipophilicity, but other, less obvious parameters govern
the amount of radioactivity clearing through the liver (3, 22, 23,
24). On other hand, the complex charge does not seem to be very
relevant in their in vivo behavior, at least in what concerns low
negative-charged complexes. The blood retention of the chelates
also correlates better with their binding to HSA than with their
hydrophilic/lipophilic ratio.
The results of the present systematic structure-biodistribution
study may contribute to the optimization of the properties of the
potential radiopharmaceuticals derived from the 111In31 chelates of
DTPA.
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